Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces its unaudited interim results for the six months ended 30 June 2019.
60,000 sq. ft World-class Integrated R&D Facility at TICEL Bio Park to House 250 scientists
Catalyst Pharmaceuticals, Inc., is commenting on trading activity in its common stock and on the current state of its capital resources.
Faron announces its unaudited interim results for the six months ended 30 June 2019.
OncoCyte, a global oncology diagnostics company, recently announced that it will acquire Razor Genomics, which has developed a novel molecular diagnostic test for early-stage non-small cell lung cancer.
Using a combination of machine learning and parallel chemistry to change the way we think about treating disease
The dermatological drug maker will use Chapter 11 protection to restructure the company, including a possible sale of assets, and will delay development of its Phase III-ready psoriasis treatment.
CARB-X is awarding Procarta Biosystems, a UK-based biotech company, up to US$2.2 million in non-dilutive funding with the possibility of $7.0 million more if certain project milestones are met, to develop a new class of antibiotics to treat Gram-negative ESKAPE pathogens.
CMR Surgical Limited announces that it has raised £195 million ($240 million) to fully fund the global commercialisation of the business.
Race Oncology Limited is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has joined the Board of Directors of Race Oncology Ltd.